Apolipoprotein E ε4 Allele Is Associated with Increased Atrophy in Progressive Mild Cognitive Impairment: A Voxel-Based Morphometric StudyHämäläinen A.a · Grau-Olivares M.g · Tervo S.a · Niskanen E.b · Pennanen C.a · Huuskonen J.a · Kivipelto M.a · Hänninen T.d · Tapiola M.a · Vanhanen M.a · Hallikainen M.a · Helkala E.-L.c · Nissinen A.f · Vanninen R.L.e · Soininen H.a, d
aDepartment of Neuroscience and Neurology, University of Kuopio and Brain Research Unit, Clinical Research Center, Mediteknia, Departments of bPhysics and cPublic Health, University of Kuopio, Departments of dNeurology and eClinical Radiology, Kuopio University Hospital, Kuopio, and fNational Institute of Public Health, Helsinki, Finland; gDepartment of Psychiatry and Clinical Psychobiology, University of Barcelona, Barcelona, Spain
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Background: The apolipoprotein E (APOE) Ε4 allele is a risk factor for Alzheimer’s disease. Earlier studies have shown differences in brain structure according to the APOE Ε4 status. Objective: To assess possible differences in brain structure according to the APOE Ε4 status in mild cognitive impairment (MCI) subjects in relation to conversion to dementia. Methods: In a follow-up study of 56 MCI subjects, 13 MCI subjects progressed to dementia (PMCI) during a mean follow-up time of 31 months. Brain structure differences in both stable MCI (SMCI) and PMCI Ε4 carriers and noncarriers in the baseline MRI scan were assessed with voxel-based morphometry. Results: The SMCI Ε4 carriers had atrophy in the amygdala and hippocampus compared to the SMCI noncarriers. The PMCI Ε4 carriers revealed atrophy of the left inferior frontal gyrus and parietal cortex compared to the PMCI noncarriers. Conclusion: The rate of brain atrophy in certain brain areas may be increased in Ε4-positive MCI subjects progressing to dementia.
© 2008 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.